FDA approves prostate treatment device
This article was originally published in Clinica
The US FDA last week approved EDAP Technomed Prostatron, a device that uses microwaves to heat and destroy excess prostate tissue. The new device uses a computer-controlled system to target the prostate gland with microwave heat therapy. The procedure takes one hour and can be done on an outpatient basis with local anaesthesia.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.